CVM is the ticker symbol for CEL SCI CORP, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks CVM with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is CVM a good stock to buy?

CVM is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/CVM.

Where does 13F Pro source CVM data?

All CEL SCI CORP fundamentals and ownership data come directly from SEC EDGAR. CEL SCI CORP files with the SEC under CIK 725363. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

CEL SCI CORP(CVM)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

CEL SCI CORP (CVM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CVM is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), CEL SCI CORP reports net income of $-5.7M, free cash flow of $-4.0M. Top institutional holders of CVM by reported 13-F value include RENAISSANCE TECHNOLOGIES, VANGUARD CAPITAL MANAGEMENT, CITADEL ADVISORS, based on the most recent SEC filings. CVM trades on the NYSE exchange and files with the SEC under CIK 725363. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CEL SCI CORP directly from SEC EDGAR.

Net Income

$-5.7M

Free Cash Flow

$-4.0M

CVM key financials by period

CEL SCI CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2014	10-K/A	$264.0K	$-27.4M	—
FY 2013	10-K	$159.6K	$-9.2M	—
FY 2012	10-K	$254.6K	$-15.5M	—
FY 2011	10-K	$956.2K	$-25.7M	—

Institutions holding CVM

Institutional investors reporting a position in CEL SCI CORP on SEC Form 13F.
Institution	Shares	Value	Reported
RENAISSANCE TECHNOLOGIES	572,460	$595.4K	2026-06-30
VANGUARD CAPITAL MANAGEMENT	543,079	$564.8K	2026-06-30
CITADEL ADVISORS	198,500	$206.4K	2026-06-30
MAI Capital Management	108,280	$112.6K	2026-06-30
GEODE CAPITAL MANAGEMENT	88,200	$91.8K	2026-06-30
COMMONWEALTH EQUITY SERVICES	51,434	$53.5K	2026-06-30
HRT FINANCIAL	51,155	$53.0K	2026-06-30
VANGUARD FIDUCIARY	49,036	$51.0K	2026-06-30
BlackRock	43,261	$45.0K	2026-06-30
BANK OF AMERICA	40,916	$42.6K	2026-06-30

SEC EDGAR: CIK 725363 →

CEL SCI CORP

CVM

NYSESmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.